Table 3.
Experimental Models | BCP Dose/Concentration/Period | Diabetic Complications | Effects and Mechanisms of BCP | References |
---|---|---|---|---|
Human mesangial cells | 6.25, 12.5 and 25 μM for 1 h and then cells stimulated with high-glucose for 24 h | Diabetic nephropathy |
|
[117] |
STZ 40 mg/kg, i.p. at wk 1 (induction), STZ 120 mg/kg at wk 3, (reinforcement) to BALB/c female mice | 10 mg/kg/60 μL, 45 days | Diabetic neuropathic pain |
|
[115] |
B16F10 melanoma cells-induced tumor and lymph node metastasis in high-fat diet (60 kcal%) C57BL/6N mice | 0, 0.15 or 0.3% for 16 weeks with HFD | Diabetes associated cancer |
|
[123] |
Mouse femoral tissues derived bone marrow cells | 0.1–100 μM | Diabetes associated osteoporosis |
|
[122] |
CT26 colorectal tumor cells exposed to high-glucose, and CT26 cells transplanted in STZ (100 mg/kg)-induced DM in male Balb/c mice | 50 μM for 48 h in vitro and 200 mg/kg, P.O to mice for 10 days | Diabetes associated colorectal cancer |
|
[118] |
Distal symmetric polyneuropathy in patients with DM | Diet supplement containing BCP, myrrh, carnosic acid | Diabetic polyneuropathy |
|
[116] |
STZ, Streptozotocin; HFD, high fat diet; DM, diabetes mellitus; ROS, reactive oxygen species; NADPH, nicotinamide adenine dinucleotide phosphate; PPAR, Peroxisome proliferator-activated receptor.